{
    "clinical_study": {
        "@rank": "111057", 
        "acronym": "STORM", 
        "arm_group": {
            "arm_group_label": "VLA 009A (First stage), VLA 009B (Second stage)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will consist of 2 sequential parts: the first part (VLA009A)is a study of\n      intravenous CVA21 as a single agent for the treatment of 4 different advanced solid tumours;\n      the second part (VLA009B) is a study of intravenous CVA21 in combination with cytotoxic\n      therapy appropriate for the solid tumour selected in the first part. Both parts will be\n      open-label, multi-centre, ascending dose escalation (3+3 design) dose-finding and signal\n      seeking studies."
        }, 
        "brief_title": "Systemic Treatment of Resistant Metastatic Disease", 
        "condition": [
            "Non-small Cell Lung Cancer", 
            "Castrate-resistant Prostate Cancer", 
            "Melanoma", 
            "Bladder Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Melanoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant\n             prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma.\n\n          -  VLA009A: Locally advanced and/or metastatic disease for which curative surgery and/or\n             radiation therapy is not possible and judged not to be a candidate for the current\n             standard of care treatment. VLA009B: locally advanced and/or metastatic disease and\n             judged to be a candidate for the selected cytotoxic therapy to be used in combination\n             with CVA21.\n\n          -  Patients with metastatic CRPC must have progressive disease despite surgical\n             castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed\n             castrate levels of testosterone.\n\n          -  All subjects in Cohort 3 or Phase 2 dose (P2D) must have a lesion accessible for FNA\n             or core or open biopsy on day 8 of the first treatment cycle.\n\n          -  No CVA21 neutralising antibody (\u2264 1:16)\n\n          -  ECOG score 0-2\n\n          -  Life expectancy > 3 months\n\n          -  Acceptable haematological, renal and hepatic function\n\n          -  Protocol approved by local Research Ethics Committees\n\n          -  No chemotherapy, radiation therapy, hormonal treatment of immunotherapy within 28\n             days of dosing (except active ongoing hormonal therapy for CRPC)\n\n          -  Patients must give informed written consent\n\n          -  Women of childbearing potential must have negative pregnancy test\n\n          -  Measurable or evaluable disease\n\n        Exclusion Criteria:\n\n          -  Active cardiac disease\n\n          -  Women who are pregnant or lactating\n\n          -  HIV, hepatitis B or C infections\n\n          -  Serious neurologic or psychiatric disease\n\n          -  Second primary malignancy within the past 2 years (except non-melanoma skin cancer,\n             in situ carcinoma of the cervix, breast cancer)\n\n          -  Active uncontrolled infection\n\n          -  Concurrent immunosuppressive therapy and no known immunosuppressive disease other\n             than primary tumour\n\n          -  Residual effects from previous therapy that has not resolved to grade 1 or less\n\n          -  VLA009B: no medical contraindications to planned cytotoxic therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043665", 
            "org_study_id": "VLA 009", 
            "secondary_id": "2012-005256-42"
        }, 
        "intervention": {
            "arm_group_label": "VLA 009A (First stage), VLA 009B (Second stage)", 
            "intervention_name": "CVA21", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Alan Melcher"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }, 
                    "name": "St James University Hospital"
                }, 
                "investigator": {
                    "last_name": "Christy Ralph", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kevin Harrington"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Institute of Cancer Research"
                }, 
                "investigator": {
                    "last_name": "Kevin Harrington", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hardev Pandha"
                }, 
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "United Kingdom"
                    }, 
                    "name": "University of Surrey"
                }, 
                "investigator": {
                    "last_name": "Hardev Pandha", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Dose-finding and Signal-seeking Study of the Safety and Efficacy of Intravenous CAVATAK\u2122 (Coxsackievirus A21, CVA21) Alone and in Combination With Cytotoxic Chemotherapy in Patients With Late Stage Solid Tumours (NSCLC, Castrate-resistant Prostate Cancer, Melanoma, Bladder Cancer).", 
        "overall_contact": {
            "email": "h.pandha@surrey.ac.uk", 
            "last_name": "Hardev Pandha"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rate assessed according to immune-related RECIST 1.1 criteria", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043665"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Viralytics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Viralytics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}